RKVTF (RKVTF PINK) stock market data APIs
$0.0711
0(0%)
as of March 18, 2026
Try our APIs with
free plan!
RKVTF Financial Data Overview
Price chart is built with
Anychart
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer. Additionally, it signed a letter of intent with NanoPalm Ltd. to form a joint venture to co-develop novel small-molecule oncology therapeutics. The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.
Prev. Close
0.0711
Open
0.0711
High
0.0711
Low
0.0711
52 wk Range
0.0034-0.959
Market Cap
1 518 K
Shares Outstanding
21 148 K
EPS
-0.0108
Beta
-0.653
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get RKVTF data using free add-ons & libraries
Get RKVTF Fundamental Data
RKVTF Fundamental data includes:
- Net Revenue:
- EBITDA: -7 348 730
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-28
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
RKVTF News
New
Rakovina Therapeutics announces $2.0M combined financing via convertible debentures and private placement
Rakovina Therapeutics (RKVTF [https://seekingalpha.com/symbol/RKVTF]) has announced an increase in its financing to approximately $2 million [https://seekingalpha.com/pr/20408069-rakovina-therapeutics...
Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit
Rakovina Therapeutics Inc Highlights: Strategic Validation: Industry feedback confirms Rakovina’s approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors addresses criti...
Rakovina Therapeutics reports Q2 results
* Rakovina Therapeutics press release [https://seekingalpha.com/pr/20215509-rakovina-therapeutics-announces-three-month-q2-ended-june-30-2025-financial-results-and] (TSXV:RKV:CA [https://seekingal...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
